| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0004197 | Cysteine-type endopeptidase activity | Increases phenotype | PMID:34077701 |
| GO:0004563 | Beta-n-acetylhexosaminidase activity | Decreases phenotype | PMID:34415362 |
| GO:0006171 | Camp biosynthetic process | Increases phenotype | PMID:37269934 |
| GO:0006606 | Protein import into nucleus | Affects phenotype | PMID:34077701 |
| GO:0006711 | Estrogen catabolic process | Increases phenotype | PMID:28985473 |
| GO:0006855 | Xenobiotic transmembrane transport | Decreases phenotype | PMID:28414026 |
| GO:0008284 | Positive regulation of cell population proliferation | Increases phenotype | PMID:28414026 |
| GO:0010917 | Negative regulation of mitochondrial membrane potential | Increases phenotype | PMID:39855309 |
| GO:0010940 | Positive regulation of necrotic cell death | Increases phenotype | PMID:39855309 |
| GO:0030308 | Negative regulation of cell growth | Increases phenotype | PMID:37793997 |
| GO:0030316 | Osteoclast differentiation | Increases phenotype | PMID:35315182 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:37944786 |
| GO:0043123 | Positive regulation of i-kappab kinase/nf-kappab signaling | Increases phenotype | PMID:39855309 |
| GO:0043409 | Negative regulation of mapk cascade | Increases phenotype | PMID:39855309 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:34077701 |
| GO:0046415 | Urate metabolic process | Decreases phenotype | PMID:28414026 |
| GO:0046449 | Creatinine metabolic process | Decreases phenotype | PMID:28414026 |
| GO:0050729 | Positive regulation of inflammatory response | Increases phenotype | PMID:39855309 |
| GO:0051901 | Positive regulation of mitochondrial depolarization | Increases phenotype | PMID:37944786 |
| GO:0055074 | Calcium ion homeostasis | Affects phenotype | PMID:35315182 |
| GO:0072593 | Reactive oxygen species metabolic process | Affects phenotype | PMID:34077701 |
| GO:0090281 | Negative regulation of calcium ion import | Increases phenotype | PMID:34415362 |
| GO:1900086 | Positive regulation of peptidyl-tyrosine autophosphorylation | Increases phenotype | PMID:22387535 |
| GO:1900226 | Negative regulation of nlrp3 inflammasome complex assembly | Increases phenotype | PMID:39855309 |
| GO:1901992 | Positive regulation of mitotic cell cycle phase transition | Decreases phenotype | PMID:28414026 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Increases phenotype | PMID:37269934; PMID:37944786; PMID:39855309 |
| GO:2001170 | Negative regulation of atp biosynthetic process | Increases phenotype | PMID:37944786 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.